NUR 7071 Module 2 Cholesterol Case Paper: Risk Estimation, Risk Enhancers and Starting a Statin Example

Eight Point Nine Percent: Talking Through a Statin Decision at Intermediate Risk

Student Name

M.S. in Nursing, Family Nurse Practitioner, Thomas Edison State University

NUR-7071: Adult Primary Care Part I

Mentor Name

Month Day, Year

Eight Point Nine Percent: Talking Through a Statin Decision at Intermediate Risk

The Patient

Linda Moreno, an invented 58-year-old Hispanic woman who manages a dental office, came in for an annual visit. She has treated hypertension, controlled at 128/78 on lisinopril, and no diabetes. She has never smoked. Her younger brother had a heart attack at 52, and her mother had a stroke in her seventies. A fasting lipid panel showed total cholesterol of 248, LDL of 162, HDL of 44 and triglycerides of 210. Her waist circumference is 38 inches, her fasting glucose is 108 and her body mass index is 30. She walks her dog most evenings but does no other exercise. She asked whether she really needs "a pill for cholesterol" when she feels fine.

Estimating Risk

Grundy et al. (2019) describe four groups who benefit from statin therapy: adults with clinical atherosclerotic cardiovascular disease, adults with LDL of 190 or higher, people with diabetes between 40 and 75 and people of the same ages without diabetes whose LDL is 70 or higher and whose 10-year risk is 7.5 percent or more. For people in the last group, the pooled cohort equations estimate 10-year risk from age, sex, race, cholesterol, blood pressure, treatment, diabetes and smoking. Ms. Moreno's estimate was 8.9 percent, inside the guideline's intermediate range, 7.5 up to 20 percent. For this band the guideline recommends a moderate-intensity statin, aiming to lower LDL by 30 percent or more, if a risk discussion favors treatment.

Risk Enhancers

The guideline lists risk-enhancing factors that tip the decision toward treatment: a family history of premature cardiovascular disease, LDL persistently 160 or higher, metabolic syndrome, chronic kidney disease, inflammatory conditions, a history of preeclampsia or early menopause, high-risk ethnicity and elevated markers such as lipoprotein(a). Ms. Moreno has at least three: her brother's heart attack before 55, an LDL above 160 and metabolic syndrome, shown by her waist size, triglycerides, low HDL, fasting glucose and treated blood pressure. When the decision remains uncertain, the guideline suggests coronary artery calcium scoring: a score of zero supports deferring a statin in many patients, though not in those with a strong family history, while a score of 100 or more favors treatment.

How Much Statins Help

Individual data from about 170,000 participants in 26 randomized trials were pooled by an international group of trial investigators (Cholesterol Treatment Trialists' Collaboration, 2010). Each reduction of 1.0 mmol/L in LDL, about 39 mg/dL, lowered the yearly rate of major vascular events by roughly one fifth, with proportional benefits seen across groups with different starting risk and cholesterol levels. More intensive regimens produced further reductions compared with less intensive ones, and lowering LDL was associated with lower all-cause mortality without any increase in cancer or deaths from other non-vascular causes.

Prevention Beyond the Statin

Arnett et al. (2019) place lifestyle at the center of primary prevention: a diet emphasizing vegetables, fruit, legumes, nuts, whole grains and fish, 150 or more minutes of moderate exercise weekly, losing weight when it is above a healthy range and avoidance of tobacco. They also advise against routine aspirin for primary prevention in adults older than 70 and in anyone at increased bleeding risk, allowing it to be considered only selectively in adults aged 40 to 70 at higher risk. For Ms. Moreno, aspirin is not recommended. Her metabolic syndrome also calls for attention to her glucose, which is in the prediabetes range.

The Risk Discussion

The guideline describes a clinician-patient risk discussion that covers risk, enhancers, the likely benefit of therapy, side effects, cost and the patient's preferences. I explained that out of 100 women like her, about nine would be expected to have a cardiac event or stroke over the next ten years without treatment, and a statin lowering her LDL by a third or more could prevent a portion of those events. We talked about muscle aches, which are reported often but are usually not caused by the statin itself in controlled trials, and about the small rise in diabetes risk. She asked about calcium scoring. I explained that because of her brother's early heart attack, a zero score would not by itself change the recommendation, and she chose to start treatment.

Plan

She began atorvastatin at 20 mg each day, which counts as moderate intensity. A fasting lipid panel will be repeated in 4 to 12 weeks to confirm at least a 30 percent LDL reduction and check adherence, then every 3 to 12 months as needed. Baseline liver enzymes were normal. She agreed to add two brisk 30-minute walks on weekends, to work toward the Mediterranean-style eating pattern with a dietitian visit and to repeat her fasting glucose and A1C with the next lipid panel. Her blood pressure plan continues.

Cultural and Practical Considerations

Ms. Moreno cooks for her extended family on weekends and worried that diet changes would mean giving up traditional dishes. The dietitian referral focused on adjusting recipes, such as using beans, vegetables and olive oil more and fried foods less, rather than replacing them. Generic atorvastatin costs a few dollars a month at her pharmacy.

Limits

Pooled cohort equations can overestimate risk in some groups and underestimate it in others, including some Hispanic populations. The meta-analysis pooled trials that mostly enrolled people at higher risk than she is. The patient is invented.

Conclusion

Grundy and colleagues placed Ms. Moreno in the intermediate-risk band with three risk enhancers, Arnett and colleagues set lifestyle and aspirin decisions within broader prevention and the trialists' meta-analysis showed how much LDL lowering reduces major vascular events. A risk discussion in plain numbers, a moderate-intensity statin, a dietitian visit that respects her cooking and a lipid check within three months give her a plan she chose with full information.

References

Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596-e646. https://doi.org/10.1161/CIR.0000000000000678

Cholesterol Treatment Trialists' Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625